Prevención de la diabetes mellitus en los pacientes con insuficiencia cardiaca

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Revista Española de Cardiología Suplementos

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/S1131-3587(06)75311-0
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Papel de los ARA-II en el tratamiento de la hipertensión arterial. De la evidencia a la práctica clínica

  2005cited by this paper
• Factores de riesgo cardiovascular en la población española: metaanálisis de estudios transversales

  2005cited by this paper
• The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes.

  2005cited by this paper
• Type 2 diabetes is associated with left ventricular concentric remodeling in hypertensive patients.

  2005cited by this paper
• Badanie Valsartan Antihypertensive Long-term Use Evaluation (VALUE)

  2005cited by this paper
• Predictors of blood pressure control in patients with diabetes and hypertension seen in primary care clinics.

  2005cited by this paper
• Strategies to prevent type 2 diabetes

  2005cited by this paper
• A systematic review of drug therapy to delay or prevent type 2 diabetes.

  2005cited by this paper
• A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics

  2005cited by this paper
• [PREVENCAT study: control of cardiovascular risk in primary care].

  2005cited by this paper
• Insulin resistance and risk of congestive heart failure.

  2005cited by this paper
• Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure

  2005cited by this paper
• Estudio PREVENCAT: control del riesgo cardiovascular en atención primaria

  2005cited by this paper
• Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction: The Valsartan in Acute Myocardial Infarction (VALIANT) Trial

  2004cited by this paper
• The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization

  2004cited by this paper
• Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

  2004cited by this paper
• Old antihypertensives and new diabetes

  2004cited by this paper
• Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

  2004cited by this paper
• Antihypertensive therapy and new onset diabetes

  2004cited by this paper
• Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

  2004cited by this paper
• Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects

  2004cited by this paper
• Efectividad antihipertensiva y tolerabilidad de lercanidipino en diabéticos, en pacientes con hipertensión sistólica aislada y en ancianos. Análisis de subgrupos del estudio ELYPSE

  2003cited by this paper
• Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)

  2003cited by this paper
• A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

  2003cited by this paper
• A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

  2003cited by this paper
• Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

  2003cited by this paper
• Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)

  2003cited by this paper
• The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

  2003cited by this paper
• Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

  2003cited by this paper
• Utilidad de los antagonistas de los receptores de angiotensina II en la insuficiencia cardíaca

  2003cited by this paper
• Hipertensión arterial e insuficiencia cardíaca en las consultas de Atención Primaria y de Cardiología en España

  2003cited by this paper
• Hypertension and heart failure in Primary Care and Cardiology consultations of in Spain

  2003cited by this paper
• Utility of angiotensin receptor blockers in heart failure

  2003cited by this paper
• Angiotensin blockade prevents type 2 diabetes by formation of fat cells.

  2002cited by this paper
• Diabetes y corazón

  2002cited by this paper
• Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

  2002cited by this paper
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  2002cited by this paper
• Diabetes Therapeutics News

  2002cited by this paper
• Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

  2002cited by this paper
• Ramipril and the development of diabetes.

  2001cited by this paper
• Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial

  2001cited by this paper
• Impacto de la diabetes en las enfermedades cardíacas en España. Estudio CARDIOTENS 1999

  2001cited by this paper
• Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.

  2000cited by this paper
• Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients

  2000cited by this paper
• Renal implications of the renin-angiotensin-aldosterone system blockade in heart failure.

  2000cited by this paper
• Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

  1999cited by this paper
• Diabetes and decline in heart disease mortality in US adults.

  1999cited by this paper
• Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.

  1999cited by this paper
• Hyperglycemia and cardiovascular disease in type 2 diabetes.

  1999cited by this paper
• Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats

  1998cited by this paper
• Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry.

  1996cited by this paper
• Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

  1996cited by this paper
• A Prospective Population-Based Study of Microalbuminuria as a Predictor of Mortality in NIDDM

  1993cited by this paper
• Role of diabetes in congestive heart failure: the Framingham study.

  1974cited by this paper
• Hypertensive heart disease.

  1963cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Heart failure and new drugs: should we be aware?

  2009cites this paper
• Candesartan: from left ventricular hypertrophy to heart failure, a global approach

  2007cites this paper
• Beneficios adicionales del tratamiento con candesartán en la insuficiencia cardíaca. Programa CHARM

  2007cites this paper